Speaking on the above topic is Dr Juergen Engel, President & CEO, Ã†terna Zentaris, Germany. He will be presenting at the Drug Discovery World Asia 2012, part of a series of conferences at 5th Annual BioPharma Asia Convention 2012.
Dr Engel completed doctoral thesis in Synthetic Organic Chemistry and received Dr. rer. nat. in 1975 from Technical University of Braunschweig. After his habilitation (Dr. rer. nat. habil) in Pharmaceutical Chemistry at the University of Regensburg in 1985 he held appointments as adjunct professor School of Pharmacy at the University of Regensburg since 1990 and as Honorary Professor at the Technical University of Dresden since 1993. Currently, he is President and Chief Executive Officer of Ã†terna Zentaris Inc. in Quebec City, Canada, President of Ã†terna Zentaris Inc. in Warren, New Jersey, USA and Chairman and Managing Director of Ã†terna Zentaris GmbH, Frankfurt, Germany. Over the course of his career at ASTA Medica, the pharmaceutical division of Degussa AG, he invented and/or played a key role in the development and regulatory success of multiple new drugs, including CetrotideÂ®, the antihistamine Azelastine, Ifosfamide/Mesna, MiltexÂ®, ImpavidoÂ®, the analgesic KatadolonÂ®, the multidose powder inhaler NovolizerÂ® and the antiepileptic Retigabine. Several compounds are in late stage of clinical development including Perifosine for various cancer indications.
Dr Engel has authored more than 250 publications and several books, including the "Pharmaceutical Substances". He has filed more than 100 patent applications and was the recipient of the Galenus-von-Pergamon Award (Prix Galien Germany) 1995 for the development of MiltexÂ® (miltefosine). He was Chairman of the Board of the section Medicinal Chemistry of the German Chemical Society from 1997-2002, is elected member of the Scientific Advisory Board of the Biocenter of University of Wuerzburg, member of the Board of the German Pharmaceutical Association (BPI) Hesse, member of the Innovation and Technology Committee of the Chamber of Commerce Frankfurt, and member of the Board of Directors of the Canadian company Isotechnika.
Dr Engel will be speaking on the following topics:
1. Evaluating the first-in-class Erk and dual PI3K/Erk inhibitor
2. Proven in-vivo pharmalogical activities in cancer xenograft models
3. Forward looking application possibilities and development opportunities